Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

  • End date
    Aug 12, 2025
  • participants needed
  • sponsor
    Kartos Therapeutics, Inc.
Updated on 4 October 2022
platelet count
renal function
measurable disease
small molecule


This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.

Condition Merkel Cell Carcinoma
Treatment Avelumab, KRT-232
Clinical Study IdentifierNCT03787602
SponsorKartos Therapeutics, Inc.
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

For Cohort 1, 3 and 4 patients must have failed treatment with at least one PD-1 inhibitor or PD-L1 inhibitor for metastatic MCC
ECOG performance status of 0 to 1
Histologically confirmed MCC. Disease must be measurable, with at least 1 measurable lesion by RECIST 1.1
For Cohort 2, patients must not have received any anti-PD-1 or anti-PD-L1 therapy
For Cohort 3, patients must not have received any prior chemotherapy
For Cohort 4, patients must have received at least one prior line of chemotherapy
Adequate hematological, hepatic, and renal functions
MCC expressing p53WT based on any CLIA or test approved by local health authority or a validated test (Cohort 1 and 2)
MCC expressing p53WT based Central Lab test (Cohort 3 and 4)

Exclusion Criteria

For Cohort 2, subjects must not have autoimmune disease, medical conditions requiring systemic immunosuppression, prior stem cell transplant, or active infection with HBV or HCV
Grade 2 or higher QTc prolongation (>480 milli-seconds per NCI-CTCAE criteria, version 5.0)
Patients previously treated with MDM2 antagonist therapies or p53-directed therapies
History of major organ transplant
Patients with known central nervous system (CNS) metastases that are previously untreated
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note